Aurinia Pharmaceuticals (AUPH) Stock Price, News & Analysis

Company Overview

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s primary product is Lupkynis (voclosporin), an oral calcineurin inhibitor approved for use in combination with background immunosuppressive therapy to treat adult patients with active lupus nephritis, a serious kidney complication of systemic lupus erythematosus.

Lupkynis is designed to help control the underlying immune response associated with lupus nephritis and reduce the risk of progressive kidney damage. Aurinia supports the product through medical, patient-support and commercial activities, with operations serving markets including the United States and Europe.

The company traces its history to Isotechnika Pharma, a Canadian biotechnology business that adopted the Aurinia Pharmaceuticals name in 2013. Aurinia is headquartered in Victoria, British Columbia, and has maintained a commercial presence in the United States. Peter Greenleaf has served as the company’s president and chief executive officer.

Key Stats

• Today's Range: $16.06 to $16.35
• 50-Day Range: $14.57 to $17.27
• 52-Week Range: $10.34 to $19.25
• Volume: 745,434 shs
• Average Volume: 891,886 shs
• Market Capitalization: $2.14 billion
• P/E Ratio: 7.03
• Dividend Yield: N/A
• Price Target: $17.67
• Consensus Rating: Moderate Buy

Aurinia Pharmaceuticals Stock Analysis - MarketRank™

Aurinia Pharmaceuticals scored higher than 73% of companies evaluated by MarketBeat, and ranked 204th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Aurinia Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 2 buy ratings, 3 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Aurinia Pharmaceuticals is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Aurinia Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 8.86%

Earnings Growth

Earnings for Aurinia Pharmaceuticals are expected to grow by 8.86% in the coming year, from $0.79 to $0.86 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aurinia Pharmaceuticals is 7.03, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.90.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aurinia Pharmaceuticals is 7.03, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.94.

Price to Book Value per Share Ratio

Aurinia Pharmaceuticals has a P/B Ratio of 3.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.53% of the float of Aurinia Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Aurinia Pharmaceuticals has a short interest ratio ("days to cover") of 8.56.

Change versus previous month

Short interest in Aurinia Pharmaceuticals has recently decreased by 6.62%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aurinia Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Aurinia Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: 1.74

News Sentiment

Aurinia Pharmaceuticals has a news sentiment score of 1.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Aurinia Pharmaceuticals this week, compared to 3 articles on an average week.

Search Interest

Only 5 people have searched for AUPH on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.

MarketBeat Follows

5 people have added Aurinia Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aurinia Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.40% of the stock of Aurinia Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

36.83% of the stock of Aurinia Pharmaceuticals is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/13/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:AUPH
• CIK: 1600620
• Web: www.auriniapharma.com
• Phone: 250-708-4272
• Fax: 250-744-2498
• Employees: 128
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Aurinia Pharmaceuticals: $17.67
• High Price Target: $21.00
• Low Price Target: $16.00
• Potential Upside/Downside: +9.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.29
• Trailing P/E Ratio: 7.03
• Forward P/E Ratio: 20.38
• P/E Growth: N/A
• Net Income: $287.20 million
• Net Margins: 100.84%
• Pretax Margin: 51.48%
• Return on Equity: 26.11%
• Return on Assets: 19.89%

Debt

• Debt-to-Equity Ratio: 0.07
• Current Ratio: 5.42
• Quick Ratio: 4.97

Sales & Book Value

• Annual Sales: $283.05 million
• Price / Sales: 7.57
• Cash Flow: $1.01 per share
• Price / Cash Flow: 15.89
• Book Value: $4.41 per share
• Price / Book: 3.65

Miscellaneous

• Outstanding Shares: 133,050,000
• Free Float: 119,214,000
• Market Cap: $2.14 billion
• Optionable: Optionable
• Beta: 1.40